{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:24:35Z","timestamp":1783149875237,"version":"3.54.6"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472119"],"award-info":[{"award-number":["81472119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672196"],"award-info":[{"award-number":["81672196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.intimp.2019.106014","type":"journal-article","created":{"date-parts":[[2019,11,24]],"date-time":"2019-11-24T16:03:36Z","timestamp":1574611416000},"page":"106014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Flufenamic acid inhibits osteoclast formation and bone resorption and act against estrogen-dependent bone loss in mice"],"prefix":"10.1016","volume":"78","author":[{"given":"Shutao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicheng","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin'en","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.106014_b0005","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.intimp.2019.106014_b0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.intimp.2019.106014_b0015","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.intimp.2019.106014_b0020","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.intimp.2019.106014_b0025","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2019.106014_b0030","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.intimp.2019.106014_b0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2019.106014_b0040","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMcp043801","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"353","author":"Rosen","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2019.106014_b0045","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","article-title":"Cell biology of the osteoclast","volume":"27","author":"Roodman","year":"1999","journal-title":"Exp. Hematol."},{"issue":"6937","key":"10.1016\/j.intimp.2019.106014_b0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.intimp.2019.106014_b0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","article-title":"Genetic regulation of osteoclast development and function","volume":"4","author":"Teitelbaum","year":"2003","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2019.106014_b0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2019.106014_b0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH645>3.0.CO;2-Q","article-title":"Regulation of the differentiation and function of osteoclasts","volume":"192","author":"Chambers","year":"2000","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.intimp.2019.106014_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103004","article-title":"Roles of mitogen-activated protein kinases in osteoclast biology","volume":"19","author":"Lee","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2019.106014_b0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7150\/ijbs.13814","article-title":"Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation","volume":"12","author":"Lee","year":"2016","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2019.106014_b0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0006-291X(03)00695-8","article-title":"Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts","volume":"305","author":"Lee","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2019.106014_b0085","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1210\/me.2007-0237","article-title":"NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP)","volume":"22","author":"Kim","year":"2008","journal-title":"Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.intimp.2019.106014_b0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.11005\/jbm.2014.21.4.233","article-title":"Regulation of NFATc1 in osteoclast differentiation","volume":"21","author":"Kim","year":"2014","journal-title":"J. Bone. Metab."},{"issue":"5484","key":"10.1016\/j.intimp.2019.106014_b0095","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.intimp.2019.106014_b0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00296-002-0217-8","article-title":"Transdermal fentanyl for the treatment of back pain caused by vertebral osteoporosis","volume":"22","author":"Ringe","year":"2002","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.intimp.2019.106014_b0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1098-3597(01)90069-9","article-title":"Understanding NSAIDs: from aspirin to COX-2","volume":"3","author":"Green","year":"2001","journal-title":"Clin Cornerstone"},{"issue":"4","key":"10.1016\/j.intimp.2019.106014_b0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1163\/156856005774415565","article-title":"The use of NSAIDs in rheumatic disorders 2005: a global perspective","volume":"13","author":"Kean","year":"2005","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.intimp.2019.106014_b0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jbmr.5650110106","article-title":"Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group","volume":"11","author":"Bauer","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.intimp.2019.106014_b0120","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1359\/jbmr.2003.18.10.1795","article-title":"Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: Impact of cyclooxygenase selectivity","volume":"18","author":"Carbone","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.intimp.2019.106014_b0125","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00198-006-0142-x","article-title":"Canadian multicentre osteoporosis study, the effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian multicentre osteoporosis study","volume":"17","author":"Richards","year":"2006","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.intimp.2019.106014_b0130","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/s10165-008-0149-6","article-title":"The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro","volume":"19","author":"Kawashima","year":"2009","journal-title":"Mod. Rheumatol."},{"issue":"2\u20133","key":"10.1016\/j.intimp.2019.106014_b0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2007.06.030","article-title":"Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro","volume":"572","author":"Kellinsalmi","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2019.106014_b0140","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biopha.2018.10.052","article-title":"DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo","volume":"109","author":"Ishida","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.intimp.2019.106014_b0145","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.clinthera.2015.06.006","article-title":"The pathophysiology and treatment of osteoporosis","volume":"37","author":"Drake","year":"2015","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2019.106014_b0150","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.2016.11032","article-title":"Osteoporosis therapy in postmenopausal women with high risk of fracture","volume":"316","author":"Cappola","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.intimp.2019.106014_b0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.intimp.2019.106014_b0160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.intimp.2019.106014_b0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch. Osteoporos."},{"issue":"1","key":"10.1016\/j.intimp.2019.106014_b0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2008.09.012","article-title":"Osteonecrosis of the jaw: who gets it, and why?","volume":"44","author":"Reid","year":"2009","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.intimp.2019.106014_b0175","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.intimp.2019.106014_b0180","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.intimp.2019.106014_b0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.mehy.2013.03.042","article-title":"NSAIDs can have adverse effects on bone healing","volume":"81","author":"van Esch","year":"2013","journal-title":"Med. Hypotheses"},{"issue":"7","key":"10.1016\/j.intimp.2019.106014_b0190","doi-asserted-by":"crossref","DOI":"10.1097\/BRS.0b013e3181dfd163","article-title":"High-dose ketorolac affects adult spinal fusion: a meta-analysis of the effect of perioperative nonsteroidal anti-inflammatory drugs on spinal fusion","volume":"36","author":"Li","year":"2011","journal-title":"Spine (Phila Pa 1976)"},{"issue":"5","key":"10.1016\/j.intimp.2019.106014_b0195","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1302\/0301-620X.82B5.0820655","article-title":"Nonunion of the femoral diaphysis","volume":"82-B","author":"Giannoudis","year":"2000","journal-title":"J. Bone Joint Surg. British"},{"issue":"6","key":"10.1016\/j.intimp.2019.106014_b0200","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3109\/17453674.2012.747054","article-title":"Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database","volume":"83","author":"Hernandez","year":"2012","journal-title":"Acta Orthop."},{"issue":"4","key":"10.1016\/j.intimp.2019.106014_b0205","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/BOR.0b013e32836200b8","article-title":"NSAIDs and fracture healing","volume":"25","author":"Geusens","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2019.106014_b0210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.tem.2009.12.004","article-title":"Prostaglandins in bone: bad cop, good cop?","volume":"21","author":"Blackwell","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.intimp.2019.106014_b0215","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2106\/JBJS.J.01743","article-title":"The effect of nonsteroidal anti-inflammatory drug administration on acute phase fracture-healing: a review","volume":"94","author":"Kurmis","year":"2012","journal-title":"J. Bone Joint Surg. Am."},{"issue":"12","key":"10.1016\/j.intimp.2019.106014_b0220","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1172\/JCI26132","article-title":"M-CSF mediates TNF-induced inflammatory osteolysis","volume":"115","author":"Kitaura","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"145","key":"10.1016\/j.intimp.2019.106014_b0225","doi-asserted-by":"crossref","DOI":"10.3791\/59089","article-title":"Effect of anti-c-fms antibody on osteoclast formation and proliferation of osteoclast precursor in vitro","author":"Marahleh","year":"2019","journal-title":"J Vis Exp"},{"key":"10.1016\/j.intimp.2019.106014_b0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fendo.2019.00157","article-title":"Docosahexaenoic acid inhibits inflammation-induced osteoclast formation and bone resorption in vivo through GPR120 by inhibiting TNF-alpha production in macrophages and directly inhibiting osteoclast formation","volume":"10","author":"Kishikawa","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"10.1016\/j.intimp.2019.106014_b0235","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pharmthera.2013.01.012","article-title":"Flufenamic acid as an ion channel modulator","volume":"138","author":"Guinamard","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2019.106014_b0240","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3892\/ijo.2013.1891","article-title":"Flufenamic acid promotes angiogenesis through AMPK activation","volume":"42","author":"Ge","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2019.106014_b0245","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejphar.2017.01.026","article-title":"Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-kappaB inhibition and AMPK activation","volume":"798","author":"Pongkorpsakol","year":"2017","journal-title":"Eur. J. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919314730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919314730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:18:27Z","timestamp":1761585507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919314730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":49,"alternative-id":["S1567576919314730"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106014","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flufenamic acid inhibits osteoclast formation and bone resorption and act against estrogen-dependent bone loss in mice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106014"}}